Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Tools & Technology › Sequencing › Devyser Receives €750K Grant to Build Sequencing Assay for Early Detection of Transplant Rejection

Devyser Receives €750K Grant to Build Sequencing Assay for Early Detection of Transplant Rejection

Jan 19, 2021
|
staff reporter

NEW YORK – Swedish molecular diagnostics firm Devyser Diagnostics said on Tuesday that it has received a €750,000 ($909,000) grant through the Eurostars-2 program to develop a next-generation sequencing assay for monitoring graft status and early detection of rejection in kidney transplant recipients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Featured Webinar

Think Globally, Act Locally: The Importance of Coordinated Global and Community Genetic Surveillance Programs

Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Featured Webinar

Development and Commercialization of a Novel CRISPR-Based SARS CoV-2 Test

Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test. 

What's Popular?

In Molecular Diagnostics

  1. Luminex Shares Surge on Rumor of Acquisition by DiaSorin

  2. Walgreens to Sell Labcorp COVID-19 PCR Home Collection Kits Over-the-Counter

  3. Guardant Health Q4 Revenues Up 25 Percent

  4. Guardant Health Begins First Foray Into Early-Stage Cancer With Commercial MRD Test Launch

    Premium

  5. Novacyt Obtains CE Mark for Extraction-Free COVID-19 PCR Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.